IL-23 Past, Present, and Future: a Roadmap to Advancing IL-23 Science and Therapy

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Apr 30

PMID 38686385

Authors

James G Krueger

Kilian Eyerich

Vijay K Kuchroo

Christopher T Ritchlin

Maria T Abreu

M Merle Elloso

Anne Fourie

Steven Fakharzadeh

Jonathan P Sherlock

Ya-Wen Yang

Daniel J Cua

Iain B McInnes

Affiliations

Soon will be listed here.

Abstract

Interleukin (IL)-23, an IL-12 cytokine family member, is a hierarchically dominant regulatory cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis, psoriatic arthritis, and inflammatory bowel disease. We review IL-23 biology, IL-23 signaling in IMIDs, and the effect of IL-23 inhibition in treating these diseases. We propose studies to advance IL-23 biology and unravel differences in response to anti-IL-23 therapy. Experimental evidence generated from these investigations could establish a novel molecular ontology centered around IL-23-driven diseases, improve upon current approaches to treating IMIDs with IL-23 inhibition, and ultimately facilitate optimal identification of patients and, thereby, outcomes.

Citing Articles

IL-23 tunes inflammatory functions of human mucosal-associated invariant T cells.

Camard L, Stephen T, Yahia-Cherbal H, Guillemot V, Mella S, Baillet V iScience. 2025; 28(2):111898.

PMID: 40008359 PMC: 11850163. DOI: 10.1016/j.isci.2025.111898.

Role of Mirikizumab in the Treatment of Inflammatory Bowel Disease-From Bench to Bedside.

Colwill M, Baillie S, Clough J, Pollok R, Poullis A, Patel K J Clin Med. 2025; 14(3).

PMID: 39941671 PMC: 11818495. DOI: 10.3390/jcm14031001.

Evidence of Inflammatory Network Disruption in Chronic Venous Disease: An Analysis of Circulating Cytokines and Chemokines.

Fraile-Martinez O, Garcia-Montero C, Gomez-Lahoz A, Sainz F, Bujan J, Barrena-Blazquez S Biomedicines. 2025; 13(1).

PMID: 39857734 PMC: 11763091. DOI: 10.3390/biomedicines13010150.

NF-κB-Inducing Kinase Is Essential for Effective c-Rel Transactivation and Binding to the Promoter in Macrophages.

Cuesta N, Staniszewska A, Moreno C, Punzon C, Fresno M Biology (Basel). 2025; 14(1).

PMID: 39857264 PMC: 11760456. DOI: 10.3390/biology14010033.

The Role of Metabolic Syndrome in Psoriasis Treatment Response: A One-Year Comparative Analysis of PASI Progression.

Mustata M, Ionescu M, Radu L, Neagoe C, Ahritculesei R, Cimpeanu R Diagnostics (Basel). 2025; 14(24.

PMID: 39767248 PMC: 11675552. DOI: 10.3390/diagnostics14242887.

References

Jain R, Chen Y, Kanno Y, Joyce-Shaikh B, Vahedi G, Hirahara K . Interleukin-23-Induced Transcription Factor Blimp-1 Promotes Pathogenicity of T Helper 17 Cells. Immunity. 2016; 44(1):131-142. PMC: 11608061. DOI: 10.1016/j.immuni.2015.11.009. View

Sabat R, Ouyang W, Wolk K . Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov. 2014; 13(1):21-38. DOI: 10.1038/nrd4176. View

Eftychi C, Schwarzer R, Vlantis K, Wachsmuth L, Basic M, Wagle P . Temporally Distinct Functions of the Cytokines IL-12 and IL-23 Drive Chronic Colon Inflammation in Response to Intestinal Barrier Impairment. Immunity. 2019; 51(2):367-380.e4. DOI: 10.1016/j.immuni.2019.06.008. View

Lee Y, Awasthi A, Yosef N, Quintana F, Xiao S, Peters A . Induction and molecular signature of pathogenic TH17 cells. Nat Immunol. 2012; 13(10):991-9. PMC: 3459594. DOI: 10.1038/ni.2416. View

Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441(7090):235-8. DOI: 10.1038/nature04753. View

Liang D, Zuo A, Shao H, Born W, OBrien R, Kaplan H . IL-23 receptor expression on γδ T cells correlates with their enhancing or suppressive effects on autoreactive T cells in experimental autoimmune uveitis. J Immunol. 2013; 191(3):1118-25. PMC: 3720691. DOI: 10.4049/jimmunol.1300626. View

Veldhoen M, Hocking R, Atkins C, Locksley R, Stockinger B . TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006; 24(2):179-89. DOI: 10.1016/j.immuni.2006.01.001. View

Byrd A, Belkaid Y, Segre J . The human skin microbiome. Nat Rev Microbiol. 2018; 16(3):143-155. DOI: 10.1038/nrmicro.2017.157. View

Kvedaraite E, Lourda M, Idestrom M, Chen P, Olsson-Akefeldt S, Forkel M . Tissue-infiltrating neutrophils represent the main source of IL-23 in the colon of patients with IBD. Gut. 2015; 65(10):1632-41. DOI: 10.1136/gutjnl-2014-309014. View

10.

. Efficacy and Safety of Combination Induction Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis: Results Through Week 12 of a Phase 2a Randomized, Double-Blind, Active-Controlled,.... Gastroenterol Hepatol (N Y). 2022; 18(4 Suppl 1):9-10. PMC: 9122068. View

11.

Albanesi C, Madonna S, Gisondi P, Girolomoni G . The Interplay Between Keratinocytes and Immune Cells in the Pathogenesis of Psoriasis. Front Immunol. 2018; 9:1549. PMC: 6043636. DOI: 10.3389/fimmu.2018.01549. View

12.

Zhou L, Wang Y, Wan Q, Wu F, Barbon J, Dunstan R . A non-clinical comparative study of IL-23 antibodies in psoriasis. MAbs. 2021; 13(1):1964420. PMC: 8409790. DOI: 10.1080/19420862.2021.1964420. View

13.

Visvanathan S, Baum P, Salas A, Vinisko R, Schmid R, Grebe K . Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study. J Crohns Colitis. 2018; 12(10):1170-1179. PMC: 6225973. DOI: 10.1093/ecco-jcc/jjy099. View

14.

Gaffen S, Jain R, Garg A, Cua D . The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014; 14(9):585-600. PMC: 4281037. DOI: 10.1038/nri3707. View

15.

Danese S, Panaccione R, Feagan B, Afzali A, Rubin D, Sands B . Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial. Lancet Gastroenterol Hepatol. 2023; 9(2):133-146. DOI: 10.1016/S2468-1253(23)00318-7. View

16.

Reich K, Armstrong A, Langley R, Flavin S, Randazzo B, Li S . Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019; 394(10201):831-839. DOI: 10.1016/S0140-6736(19)31773-8. View

17.

Abbas A, Gregersen I, Holm S, Daissormont I, Bjerkeli V, Krohg-Sorensen K . Interleukin 23 levels are increased in carotid atherosclerosis: possible role for the interleukin 23/interleukin 17 axis. Stroke. 2015; 46(3):793-9. DOI: 10.1161/STROKEAHA.114.006516. View

18.

Blauvelt A, Leonardi C, Gooderham M, Papp K, Philipp S, Wu J . Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020; 156(6):649-658. PMC: 7142813. DOI: 10.1001/jamadermatol.2020.0723. View

19.

Morelli M, Galluzzo M, Scarponi C, Madonna S, Scaglione G, Girolomoni G . Allelic Variants of HLA-C Upstream Region, , , and Genes Involved in Epidermal Homeostasis and Barrier Function Influence the Clinical Response to Anti-IL-12/IL-23 Treatment of Patients with Psoriasis. Vaccines (Basel). 2022; 10(11). PMC: 9695538. DOI: 10.3390/vaccines10111977. View

20.

Ritchlin C, Helliwell P, Boehncke W, Soriano E, Hsia E, Kollmeier A . Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced. RMD Open. 2021; 7(1). PMC: 7880108. DOI: 10.1136/rmdopen-2020-001457. View